CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

SEATTLE, Nov. 6, 2019

The details of the oral presentation are as follows:

Abstract Title: Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
Session Date: Monday, December 9, 2019
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 10:30 AM
Publication Number: 667
Location: Orange County Convention Center, W311EFGH  

The details of the poster presentations are as follows:

Abstract Title: The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: Poster I
Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM - 7:30 PM
Publication Number: 1674
Location: Orange County Convention Center, Hall B

Abstract Title: Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: Poster III 
Date: Monday, December 9, 2019 
Presentation Time: 6:00 PM - 8:00 PM 
Publication Number: 4175 
Location: Orange County Convention Center, Hall B

Abstract Title: Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: Poster III
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM 
Publication Number: 4195
Location: Orange County Convention Center, Hall B